Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can At-Home eye scans personalize wet AMD treatment?

NCT ID NCT07744984

Disease control Sponsor: Rabin Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This study tests whether a home eye-scanning device can improve care for people with wet age-related macular degeneration (AMD) who are switching to the medication faricimab. Participants will scan their own retinas at home several times a week, and the images will be sent to their doctors for review. The goal is to see if this frequent monitoring helps detect changes sooner and supports more personalized treatment decisions, potentially extending the time between injections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
faricimab (an anti-VEGF eye injection) plus a home optical coherence tomography (OCT) device for self-imaging
What this could lead to
If it works, this could show that home eye scans help doctors adjust wet AMD treatment faster and more precisely, potentially leading to better vision outcomes and fewer clinic visits.
What could go wrong
This is a very small study (12 people) and early-stage, so results may not apply broadly. The home device requires regular self-imaging, which may be challenging, and faricimab may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12 people

The number who actually took part.

Started

Jul 2024

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include up to 20 patients diagnosed with nvAMD who received at least 3 consecutive anti VEGF injections without showing a treatment response, as confirmed by a retina specialist, and who are being transitioned to treatment with Faricimab per the discretion of their treating retina specialist. All patients in the study will sign a consent form.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients at least 55 years of age. * Visual Acuity of 20/320 or better in the study eye. * Diagnosis of active nvAMD that was treated with at least 3 consecutive anti-VEGF injections. * Patients are meeting the standard care criteria to switch to a second line drug. * Patients are able and willing to conduct daily OCT self-imaging at home for the duration of the study. * Patient signing a consent form Exclusion Criteria: * Patients with any other retinal disease in the study eye requiring steroidal or anti-VEGF injections (anti-VEGF injections during the study period must be for nvAMD). * Any concurrent ocular condition precluding acquisition of OCT images (eg, severe blepharoptosis, corneal opacification, cataract etc) in the study eye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration (AMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration (AMD) Neovascular age-related macular degeneration (NAMD) wet AMD

Contacts and locations

Locations

  • Rabin Medical Center

    Petah Tikva, Israel, 4941492, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.